Placement and Entitlement Offer to Fund Phase III Trials
Filed with ASX · · 5 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Key Opinion Leader Presentation
- Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
- Japan Patent Allowance for RECCE Anti-Infectives
- Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
- Positive Phase II Data from Clinical Trial of R327 Gel
Later from Recce Pharmaceuticals
- Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
- Phase II Clinical Trial Receives Additional Approval for DFI
- Entitlement Offer - Offer Booklet and Access Letter
- Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
- Recce Enters into USA Department of Defense R&D Agreement
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals